Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 05 2022
Historique:
received: 07 02 2022
accepted: 28 04 2022
entrez: 21 5 2022
pubmed: 22 5 2022
medline: 25 5 2022
Statut: epublish

Résumé

Assessment of the intensity, dynamics and determinants of the antibody response after SARS-CoV-2 infection or vaccination in the general population is critical to guide vaccination policies. This study characterized the anti-spike IgG titers in 13,971 participants included in a French multicohort population-based serological survey on COVID-19 between April and October 2020 and followed-up with serological testing between May and October 2021. Eight follow-up profiles were defined depending on SARS-CoV-2 infection (0, 1 or 2) and COVID-19 vaccination (0, 1, 2 or 3). The anti-spike titer was lower in adults with no vaccination even in case of infection or reinfection, while it was higher in adults with infection followed by vaccination. The anti-spike titer was negatively correlated with age in vaccinated but uninfected adults, whereas it was positively correlated with age in unvaccinated but infected adults. In adults with 2 vaccine injections and no infection, the vaccine protocol, age, gender, and time since the last vaccine injection were independently associated with the anti-spike titer. The decrease in anti-spike titer was much more rapid in vaccinated than in infected subjects. These results highlight the strong heterogeneity of the antibody response against SARS-CoV-2 in the general population depending on previous infection and vaccination.

Identifiants

pubmed: 35597776
doi: 10.1038/s41598-022-11787-4
pii: 10.1038/s41598-022-11787-4
pmc: PMC9123863
doi:

Substances chimiques

Antibodies, Viral 0
COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8622

Investigateurs

Fabrice Carrat (F)
Marie Zins (M)
Gianluca Severi (G)
Mathilde Touvier (M)
Hélène Blanché (H)
Jean-François Deleuze (JF)
Xavier de Lamballerie (X)
Clovis Lusivika-Nzinga (C)
Gregory Pannetier (G)
Nathanael Lapidus (N)
Isabelle Goderel (I)
Céline Dorival (C)
Jérôme Nicol (J)
Olivier Robineau (O)
Sofiane Kab (S)
Adeline Renuy (A)
Stéphane Le-Got (S)
Céline Ribet (C)
Mireille Pellicer (M)
Emmanuel Wiernik (E)
Marcel Goldberg (M)
Fanny Artaud (F)
Pascale Gerbouin-Rérolle (P)
Mélody Enguix (M)
Camille Laplanche (C)
Roselyn Gomes-Rima (R)
Lyan Hoang (L)
Emmanuelle Correia (E)
Alpha Amadou Barry (AA)
Nadège Senina (N)
Julien Allegre (J)
Fabien Szabo de Edelenyi (FS)
Nathalie Druesne-Pecollo (N)
Younes Esseddik (Y)
Serge Hercberg (S)
Mélanie Deschasaux (M)
Hélène Blanché (H)
Jean-Marc Sébaoun (JM)
Jean-Christophe Beaudoin (JC)
Laetitia Gressin (L)
Valérie Morel (V)
Ouissam Ouili (O)
Jean-François Deleuze (JF)
Laetitia Ninove (L)
Stéphane Priet (S)
Paola Mariela Saba Villarroel (PMS)
Toscane Fourié (T)
Souand Mohamed Ali (SM)
Abdenour Amroun (A)
Morgan Seston (M)
Nazli Ayhan (N)
Boris Pastorino (B)

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
N Engl J Med. 2022 Jan 13;386(2):105-115
pubmed: 34942066
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
JAMA Netw Open. 2021 Sep 1;4(9):e2124331
pubmed: 34473262
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Int J Epidemiol. 2021 Nov 10;50(5):1458-1472
pubmed: 34293141
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Infection. 2022 Feb;50(1):257-262
pubmed: 34822130
Clin Microbiol Infect. 2022 Mar;28(3):450.e1-450.e4
pubmed: 34838782
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139419
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062724
JAMA. 2021 Nov 16;326(19):1930-1939
pubmed: 34724027
Lancet Healthy Longev. 2021 Sep;2(9):e544-e553
pubmed: 34430954
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Immunity. 2021 Dec 14;54(12):2893-2907.e5
pubmed: 34614412
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Antiviral Res. 2020 Sep;181:104880
pubmed: 32679056
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Vaccine. 2007 May 22;25(21):4324-33
pubmed: 17445955
J Infect. 2022 Feb;84(2):248-288
pubmed: 34560135
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675
Nat Med. 2021 Dec;27(12):2136-2143
pubmed: 34728831

Auteurs

Fabrice Carrat (F)

Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Inserm, Département de santé publique, Hôpital Saint-Antoine, APHP, 27 rue Chaligny, 75571, Paris Cedex 12, France. fabrice.carrat@iplesp.upmc.fr.

Paola Mariela Saba Villarroel (PMS)

Unité des Virus Émergents, UVE, IRD 190, INSERM 1207, Aix Marseille Univ, IHU Méditerranée Infection, Marseille, France.

Nathanael Lapidus (N)

Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Inserm, Département de santé publique, Hôpital Saint-Antoine, APHP, 27 rue Chaligny, 75571, Paris Cedex 12, France.

Toscane Fourié (T)

Unité des Virus Émergents, UVE, IRD 190, INSERM 1207, Aix Marseille Univ, IHU Méditerranée Infection, Marseille, France.

Hélène Blanché (H)

Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.

Céline Dorival (C)

Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Inserm, Paris, France.

Jérôme Nicol (J)

Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Inserm, Paris, France.

Jean-François Deleuze (JF)

Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.

Olivier Robineau (O)

Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Inserm, Paris, France.

Mathilde Touvier (M)

Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, Epidemiology and Statistics Research Center - University of Paris (CRESS), Bobigny, France.

Gianluca Severi (G)

CESP UMR1018, UVSQ, Inserm, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Department of Statistics, Computer Science and Applications, University of Florence, Florence, Italy.

Marie Zins (M)

Paris University, Paris, France.
UVSQ, Inserm UMS 11, Université Paris-Saclay, Université de Paris, Villejuif, France.

Xavier de Lamballerie (X)

Unité des Virus Émergents, UVE, IRD 190, INSERM 1207, Aix Marseille Univ, IHU Méditerranée Infection, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH